Clazosentan for patients with subarachnoid haemorrhage: Lessons learned - Authors' reply

R. Loch Macdonald; Randall T. Higashida; Emanuela Keller; Stephan A. Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Doris Bach; Aline Frey; Angelina Marr; Sébastien Roux; Neal Kassell

doi:10.1016/S1474-4422(11)70217-4

Clazosentan for patients with subarachnoid haemorrhage: Lessons learned - Authors' reply

R. Loch Macdonald, Randall T. Higashida, Emanuela Keller, Stephan A. Mayer, Andy Molyneux, Andreas Raabe, Peter Vajkoczy, Isabel Wanke, Doris Bach, Aline Frey, Angelina Marr, Sébastien Roux, Neal Kassell

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	871-872
Number of pages	2
Journal	The Lancet Neurology
Volume	10
Issue number	10
DOIs	https://doi.org/10.1016/S1474-4422(11)70217-4
State	Published - Oct 2011
Externally published	Yes

Access to Document

10.1016/S1474-4422(11)70217-4

Cite this

@article{1b1572f0fea24b8797d2f252a343acbc,

title = "Clazosentan for patients with subarachnoid haemorrhage: Lessons learned - Authors' reply",

author = "Macdonald, {R. Loch} and Higashida, {Randall T.} and Emanuela Keller and Mayer, {Stephan A.} and Andy Molyneux and Andreas Raabe and Peter Vajkoczy and Isabel Wanke and Doris Bach and Aline Frey and Angelina Marr and S{\'e}bastien Roux and Neal Kassell",

note = "Funding Information: RLM receives grant support from, and has been a consultant for, Actelion Pharmaceuticals, and is chief scientific officer of Edge Therapeutics. RTH is a consultant and has been a board member for Actelion Pharmaceuticals. EK is a consultant for and has received research grants and travel support from Actelion Pharmaceuticals, has been a board member for Roche Diagnostics, has received grant support from the Commission for Techniques and Innovation, Swiss National Science Foundation, and is a stockholder in NeMoDevices. SAM is a consultant for and has received travel support from Actelion Pharmaceuticals. AM is a consultant for Actelion Pharmaceuticals, has been a consultant for Micrus Endovascular, has given expert testimony for Medical Expert Witness UK, and has received grants for undertaking the Cerecyte Trial and ISAT Trial, and grants from Micrus and MRC. DB, AF, AMa, and SR are employees and stock holders of, and have received travel expenses from, Actelion Pharmaceuticals. NK is a consultant for and has received travel support from Actelion Pharmaceuticals and has been a consultant for Edge Therapeutics. PV, IW, and AR declare that they have no conflicts of interest.",

year = "2011",

month = oct,

doi = "10.1016/S1474-4422(11)70217-4",

language = "English",

volume = "10",

pages = "871--872",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd.",

number = "10",

}

TY - JOUR

T1 - Clazosentan for patients with subarachnoid haemorrhage

T2 - Lessons learned - Authors' reply

AU - Macdonald, R. Loch

AU - Higashida, Randall T.

AU - Keller, Emanuela

AU - Mayer, Stephan A.

AU - Molyneux, Andy

AU - Raabe, Andreas

AU - Vajkoczy, Peter

AU - Wanke, Isabel

AU - Bach, Doris

AU - Frey, Aline

AU - Marr, Angelina

AU - Roux, Sébastien

AU - Kassell, Neal

N1 - Funding Information: RLM receives grant support from, and has been a consultant for, Actelion Pharmaceuticals, and is chief scientific officer of Edge Therapeutics. RTH is a consultant and has been a board member for Actelion Pharmaceuticals. EK is a consultant for and has received research grants and travel support from Actelion Pharmaceuticals, has been a board member for Roche Diagnostics, has received grant support from the Commission for Techniques and Innovation, Swiss National Science Foundation, and is a stockholder in NeMoDevices. SAM is a consultant for and has received travel support from Actelion Pharmaceuticals. AM is a consultant for Actelion Pharmaceuticals, has been a consultant for Micrus Endovascular, has given expert testimony for Medical Expert Witness UK, and has received grants for undertaking the Cerecyte Trial and ISAT Trial, and grants from Micrus and MRC. DB, AF, AMa, and SR are employees and stock holders of, and have received travel expenses from, Actelion Pharmaceuticals. NK is a consultant for and has received travel support from Actelion Pharmaceuticals and has been a consultant for Edge Therapeutics. PV, IW, and AR declare that they have no conflicts of interest.

PY - 2011/10

Y1 - 2011/10

UR - http://www.scopus.com/inward/record.url?scp=80052990780&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(11)70217-4

DO - 10.1016/S1474-4422(11)70217-4

M3 - Letter

C2 - 21939894

AN - SCOPUS:80052990780

SN - 1474-4422

VL - 10

SP - 871

EP - 872

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 10

ER -